Table S1.
Gene expression profile, grouped by various factors
| Parameters | N | dCK | CDA | dCMPD | hENT1 | Topo-IIa | dCK/CDA | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 25 | 75 | Median | 25 | 75 | Median | 25 | 75 | Median | 25 | 75 | Median | 25 | 75 | Median | 25 | 75 | ||
| Bone marrow | |||||||||||||||||||
| AML classification APML (M3) with t(15:17) AML without maturation (M1) AML with maturation (M2) Others |
17 14 40 11 |
0.03 0.05 0.03 0.01 |
0.00 0.00 0.00 0.00 |
0.90 3.10 0.61 0.29 |
1.29 0.52 0.50 0.44 |
0.02 0.01 0.06 0.00 |
5.52 10.85 2.71 3.17 |
0.77 0.97 0.59 0.13 |
0.39 0.29 0.10 0.06 |
1.49 13.47 0.90 0.44 |
1.71 3.26 1.50 0.47 |
0.04 0.00 0.02 0.18 |
3.02 14.44 3.64 1.08 |
19.27 18.25 19.53 14.82 |
6.61 8.80 8.86 2.54 |
123.5 119.4 39.95 17.49 |
0.35 0.42 0.11 0.19 |
0.00 0.00 0.00 0.00 |
1.33 13.44 0.96 0.96 |
| APML vs others APML (M3) All others (Poor) |
17 61 |
0.03 0.03 |
0.00 0.00 |
0.90 0.67 |
1.29 0.54 |
0.02 0.06 |
5.52 3.28 |
0.77 0.54 |
0.39 0.13 |
1.49 1.15 |
1.71 1.56 |
0.04 0.10 |
3.02 4.10 |
19.27 17.24 |
6.61 8.68 |
123.5 43.57 |
0.35 0.12 |
0.00 0.00 |
1.33 0.98 |
| Myeloperoxidase status Negative Positive |
13 58 |
0.03 0.04 |
0.00 0.00 |
0.68 1.00 |
1.27 0.52 |
0.04 0.01 |
5.31 2.90 |
0.38 0.65 |
0.08 0.26 |
0.79 1.33 |
0.47 2.14 |
0.04 0.33 |
2.76 4.30 |
15.72 17.33 |
7.74 7.03 |
483.5 40.34 |
0.15 0.26 |
0.01 0.00 |
0.66 2.10 |
| Pre or postchemotherapy sample Prechemo Postchemo |
32 50 |
0.01 0.04 |
0.00 0.00 |
0.90 0.67 |
0.36 1.30 |
0.01 0.05 |
1.65 6.23 |
0.72 0.51 |
0.13 0.13 |
1.43 0.98 |
1.64 1.31 |
0.04 0.04 |
3.89 3.61 |
13.36 18.23 |
6.84 7.34 |
87.02 61.95 |
0.96 0.09 |
0.01 0.00 |
3.29 0.96 |
| Remission status Resistant Relapse Remission |
32 15 35 |
0.04 0.08 0.01 |
0.00 0.00 0.00 |
1.07 0.82 0.53 |
0.88 0.38 0.45 |
0.12 0.01 0.01 |
4.85 6.76 2.54 |
0.68 0.50 0.62 |
0.24 0.07 0.09 |
1.44 1.13 0.86 |
3.11 1.84 0.92 |
0.32 0.21 0.01 |
4.64 8.76 2.43 |
17.17 15.93 19.27 |
6.84 7.57 6.64 |
93.13 32.37 100.8 |
0.18 0.05 0.65 |
0.00 0.00 0.00 |
0.96 0.96 2.02 |
| Survival Dead Alive |
37 42 |
0.04 0.02 |
0.00 0.00 |
0.90 0.61 |
0.54 0.76 |
0.02 0.01 |
3.51 2.89 |
0.49 0.65 |
0.08 0.29 |
1.24 0.94 |
1.64 1.36 |
0.12 0.04 |
4.02 3.75 |
15.93 19.12 |
6.93 8.08 |
48.48 61.95 |
0.14 0.27 |
0.00 0.00 |
0.98 1.77 |
| Blood | |||||||||||||||||||
| AML classification APML (M3) with t(15:17) AML without maturation (M1) AML with maturation (M2) Others |
14 13 38 12 |
0.56 0.21 0.00 0.11 |
0.00 0.00 0.00 0.01 |
1.33 1.61 0.43 1.04 |
1.22 1.03 0.24 0.35 |
0.04 0.09 0.01 0.04 |
2.20 2.90 2.25 2.35 |
0.60 1.68 0.44 0.58 |
0.28 0.54 0.02 0.19 |
1.31 2.98 1.04 2.21 |
2.22 2.37 0.74 1.22 |
0.31 0.05 0.01 0.66 |
3.63 5.66 2.14 4.11 |
8.55 7.57 6.18 6.55 |
2.28 2.89 0.37 3.72 |
18.72 16.03 24.57 416.2 |
0.65 0.05 0.21 0.61 |
0.00 0.00 0.00 0.02 |
0.95 5.21 1.01 241.9 |
| APML vs others APML (M3) All others (Poor) |
14 58 |
0.56 0.00 |
0.00 0.00 |
1.33 0.66 |
1.22 0.52 |
0.04 0.03 |
2.20 2.45 |
0.60 0.53 |
0.28 0.15 |
1.31 1.52 |
2.22 0.98 |
0.31 0.02 |
3.63 3.23 |
8.55 5.56 |
2.28 1.68 |
18.72 14.55 |
0.65 0.06 |
0.00 0.00 |
0.95 1.46 |
| Myeloperoxidase status Negative Positive |
12 55 |
0.11 0.00 |
0.00 0.00 |
1.46 0.81 |
1.28 0.69 |
0.05 0.03 |
2.45 2.19 |
0.21 0.75 |
0.00 0.29 |
0.60 1.47 |
0.47 1.24 |
0.01 0.07 |
2.98 3.28 |
6.78 7.57 |
2.91 1.99 |
81.44 15.13 |
0.71 0.06 |
0.02 0.00 |
0.96 1.53 |
| Pre or postchemotherapy sample Prechemo Postchemo |
31 46 |
0.01 0.03 |
0.00 0.00 |
1.19 0.66 |
0.14 1.20 |
0.01 0.05 |
1.20 3.94 |
0.77 0.50 |
0.23 0.17 |
1.84 1.20 |
1.40 0.79 |
0.03 0.03 |
3.35 2.95 |
7.49 7.22 |
1.83 1.92 |
14.36 24.57 |
0.92 |
0.00 |
1.43 |
| Remission status Resistant Relapse Remission |
31 15 31 |
0.00 0.05 0.09 |
0.00 0.00 0.00 |
0.34 0.63 1.11 |
0.64 0.21 0.85 |
0.03 0.01 0.03 |
1.56 2.42 2.55 |
0.91 0.41 0.74 |
0.23 0.17 0.17 |
1.84 0.62 1.40 |
0.90 0.74 1.61 |
0.00 0.02 0.41 |
3.21 4.61 2.86 |
4.68 1.56 9.37 |
1.23 0.24 3.90 |
14.36 57.38 23.06 |
0.02 0.96 0.75 |
0.00 0.00 0.02 |
0.96 4.50 0.96 |
| Survival Dead Alive |
35 39 |
0.03 0.01 |
0.00 0.00 |
0.39 1.10 |
0.69 0.64 |
0.05 0.01 |
2.42 2.19 |
0.54 0.74 |
0.22 0.24 |
1.31 1.44 |
0.80 1.54 |
0.01 0.07 |
3.21 3.28 |
5.88 7.57 |
2.04 1.83 |
23.37 15.13 |
0.06 0.75 |
0.00 0.00 |
1.88 0.96 |
Note: The values are given as median and IQR (25th–75th percentile).
Abbreviations: AML, acute myeloid leukemia; CDA, cytidine deaminase; dCK, deoxycytidine kinase; dCMPD, deoxycytidine monophosphate deaminase; hENT1, human equilibrative nucleoside transporter 1; Topo-IIa, topoisomerase IIα.